Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
ASKA Pharmaceutical Holdings Co., Ltd. ( (JP:4886) ) has issued an update.
ASKA Pharmaceutical Holdings Co., Ltd. has received a statement of intent from Dalton Investments, Nippon Active Value Fund PLC, and NAVF Select LLC regarding a large-scale purchase of the company’s share certificates. In response, ASKA has delivered an information list to these entities, requesting necessary information for shareholders and the board of directors to evaluate the purchase. This move is part of ASKA’s response policy to ensure transparency and informed decision-making in light of potential acquisition implications.
The most recent analyst rating on (JP:4886) stock is a Buy with a Yen2849.00 price target. To see the full list of analyst forecasts on ASKA Pharmaceutical Holdings Co., Ltd. stock, see the JP:4886 Stock Forecast page.
More about ASKA Pharmaceutical Holdings Co., Ltd.
ASKA Pharmaceutical Holdings Co., Ltd. operates in the pharmaceutical industry, focusing on the development and distribution of pharmaceutical products. The company is based in Minato-ku, Tokyo, and is led by President and Representative Director Sohta Yamaguchi.
Average Trading Volume: 44,933
Technical Sentiment Signal: Buy
Current Market Cap: Yen67.6B
For an in-depth examination of 4886 stock, go to TipRanks’ Overview page.